AptarGroup, Inc. (ATR) Q2 2025 Earnings Call Transcript

AptarGroup reported a strong Q2 2025, exceeding guidance with adjusted EPS up 18% to $1.66 and core sales increasing 3%, largely driven by robust performance in its Pharma and Closures segments. Pharma saw significant growth in Prescription, Injectables, and Active Materials, though European Consumer Healthcare faced headwinds from excess inventory and normalizing Naloxone sales, which now constitute 5% of Pharma revenue. Closures delivered 7% core sales growth and expanded margins, while the Beauty segment navigated Prestige market softness with growth in Masstige and Personal Care. Strategically, Aptar acquired Mod3 Pharma's clinical trial manufacturing capabilities to bolster early-stage drug delivery services and increased its BTY joint venture ownership. The company anticipates Q3 adjusted EPS of $1.53-$1.61, noting a $0.06-$0.07 negative impact from significant legal expenses related to intellectual property litigation, which are expected to persist for several quarters.

Analysis

AptarGroup (NYSE:ATR) delivered a strong second quarter, with adjusted EPS of $1.66 representing an 18% year-over-year increase and surpassing the high end of its guidance. Core sales grew 3%, driven by robust performance in the Pharma and Closures segments. The Pharma segment's 3% core sales growth was underpinned by strong demand in its Prescription (+8%), Injectables (+9%), and Active Materials (+11%) divisions. However, this strength was significantly offset by a 14% decline in Consumer Healthcare, attributed to prolonged customer inventory destocking in Europe. Management also flagged a key headwind: the normalization of sales for Naloxone emergency medicines, which now constitute 5% of Pharma revenue and face demand uncertainty. The Closures segment was a standout, posting 7% core sales growth and a 130-basis-point margin improvement to 16.9%, validating its recent consolidation strategy. The Beauty segment showed resilience with a 1% core sales increase, navigating softness in Prestige fragrance due to trade uncertainties with offsetting strength in Masstige and Personal Care. Looking ahead, Q3 adjusted EPS is guided to $1.53-$1.61, a range that incorporates a significant new headwind of $0.06-$0.07 per share from legal expenses related to defending the company's intellectual property. While the balance sheet remains strong with a 1.19x leverage ratio and capital returns were accelerated, the outlook is tempered by the legal costs, normalizing Naloxone sales, and continued challenges in European consumer health.

Key Decisions for Investors

• Investors should closely monitor the growth trajectory of the Injectables and Active Materials divisions to gauge their ability to offset the guided-down normalization in Naloxone sales and persistent weakness in European Consumer Healthcare.
• The newly disclosed legal expenses, impacting Q3 EPS by $0.06-$0.07, are a material headwind expected to persist for several quarters; models should be adjusted for this recurring cost and monitored for any change in its scope or duration.
• Consider the potential for a rebound in the Beauty segment, as the recent U.S.-EU trade deal may remove the tariff uncertainty that has suppressed demand in the high-margin Prestige fragrance market.
• Note the company's confidence signaled by its accelerated capital return program, having repurchased $150 million in shares in H1, which provides a floor for shareholder returns amidst the operational headwinds.